To spot these investment opportunities, Wall Street pros recommend taking a step back and focusing on the bigger picture, telling investors to pay close attention to both upside potential and what the analyst community has to say.Part of the excitement surrounding the company is based on the recent positive Phase 3 study data for its vosoritide therapy in achondroplasia, a disorder characterized by dwarfism, which was announced on December 16.